Vera Therapeutics

Yahoo Finance • 3 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics grante... Full story

Yahoo Finance • 13 days ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story

Yahoo Finance • 20 days ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 23 days ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 23 days ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 23 days ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 23 days ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 28 days ago

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Key Points Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased in val... Full story

Yahoo Finance • last month

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • last month

Vera Therapeutics Appoints Christopher Hite to Board of Directors

BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 2 months ago

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estima... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics prices public offering to raise $261M at $42.50 a share

Vera Therapeutics (VERA [https://seekingalpha.com/symbol/VERA]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20334494-vera-therapeutics-announces-pricing-of-public-offering-of-class-a-common-stock]... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics announces $200M public offering

* Vera Therapeutics (NVSDAQ:ERA) stated [https://seekingalpha.com/pr/20332409-vera-therapeutics-announces-proposed-public-offering-of-class-a-common-stock] on Monday that it had commenced a public offering to issue and sell $200M of shar... Full story

Yahoo Finance • 4 months ago

Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment?

Vera Therapeutics recently appointed James R. Meyers, a biopharmaceutical executive with more than three decades of commercial leadership at companies including Gilead and AstraZeneca, to its Board of Directors. Meyers’ track record in lea... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)The safety profile of atac... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025Biologics License... Full story

Yahoo Finance • 6 months ago

Is Waystar a Buy After Investment Company Capricorn Fund Managers Makes the Stock Its Top Holding?

Key Points Capricorn Fund Managers initiated a position in Waystar with 505,122 shares acquired, estimated at ~$19.15 million based on the average price during Q3 2025. The Waystar stake represents 6.4% of Capricorn Fund Managers' 13F rep... Full story